European Heart Journal Advance Access published online on August 4, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi445
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Dipartimento Malattie Cardiovascolari, Ospedale R. Silvestrini, 06100 Perugia, Italy
* To whom correspondence should be addressed. Aims The uncertainty surrounding safety of angiotensin receptor blockers (ARBs) increased after publication of experimental and clinical studies which suggested an excess risk of myocardial infarction (MI) in people treated with ARBs. Methods and results We performed a meta-analysis of randomised clinical trials, which compared ARBs with either a placebo or active drugs different from ARBs. Overall, ARBs were not associated with an excess risk of MI [odds ratio (OR): 1.03 in a random-effect model and 1.02 in a fixed-effect model]. In pre-specified subgroup analyses, incidence of MI did not differ between ARBs and either placebo (OR: 0.96; 95% CI: 0.84-1.10) or angiotensin-converting enzyme (ACE)-Inhibitors (OR: 0.99; 95% CI: 0.91-1.07). Incidence of MI was slightly higher with ARBs than with drug classes different from ACE-Inhibitors (OR: 1.16; P = 0.06 in a random-effect model and 0.017 in a fixed-effect model). Cardiovascular mortality did not differ between ARBs and drugs different from ARBs (OR: 1.00 in a random-effect model and 0.99 in a fixed-effect model) and it was slightly lesser with ARBs than with placebo (OR: 0.91; 95% CI: 0.83-0.99; P = 0.042) in a pre-specified subgroup analysis. Conclusion Our findings do not support the hypothesis that ARBs increase the risk of MI.
Received March 22, 2005
Revised July 8, 2005
Accepted July 14, 2005
Clinical research
Do angiotensin II receptor blockers increase the risk of myocardial infarction?
2 Dipartimento di Medicina Interna, University of Perugia, Perugia, Italy
Paolo Verdecchia, E-mail: verdec{at}tin.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Strauss and A. Hall RAS blockers: Does sex matter/ Re: Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure -- A population study: Marie Hudson et al. European Journal of Heart Failure 9 (2007) 602-609 Eur J Heart Fail, September 1, 2007; 9(9): 963 - 964. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Wang, Y. Li, S. S. Franklin, and M. Safar Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview Hypertension, July 1, 2007; 50(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Strauss and A. S. Hall Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox Circulation, August 22, 2006; 114(8): 838 - 854. [Full Text] [PDF]
|
|
|
|
|
|
R. T. Tsuyuki and M. A. McDonald Response to Tsuyuki and McDonald Circulation, August 22, 2006; 114(8): 855 - 860. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Strauss, E. Lonn, and S. Verma Angiotensin-II receptor blockers and coronary artery disease: 'presumed innocents': reply Eur. Heart J., June 2, 2006; 27(12): 1507 - 1508. [Full Text] [PDF]
|
|
|
|
|
|
M. Volpe, G. Tocci, and C. Savoia Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents' Eur. Heart J., June 2, 2006; 27(12): 1506 - 1507. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., June 1, 2006; 11(3): 95 - 96. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Strauss, E. M. Lonn, and S. Verma Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration Eur. Heart J., November 2, 2005; 26(22): 2351 - 2353. [Full Text] [PDF]
|
|